nodes	percent_of_prediction	percent_of_DWPC	metapath
Amphetamine—CYP2A6—Methoxsalen—psoriasis	0.225	0.392	CbGbCtD
Amphetamine—CYP2A6—Prednisolone—psoriasis	0.109	0.191	CbGbCtD
Amphetamine—CYP2D6—Hydroxyurea—psoriasis	0.0773	0.135	CbGbCtD
Amphetamine—CYP2A6—Dexamethasone—psoriasis	0.0644	0.112	CbGbCtD
Amphetamine—CYP2D6—Cholecalciferol—psoriasis	0.0468	0.0816	CbGbCtD
Amphetamine—CYP2D6—Cyclosporine—psoriasis	0.0308	0.0536	CbGbCtD
Amphetamine—CYP2D6—Dexamethasone—psoriasis	0.0203	0.0353	CbGbCtD
Amphetamine—CYP2A6—CYP2E1 reactions—CYP2S1—psoriasis	0.00332	0.0793	CbGpPWpGaD
Amphetamine—CYP2A6—Xenobiotics—CYP2S1—psoriasis	0.00206	0.0491	CbGpPWpGaD
Amphetamine—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.00186	0.0444	CbGpPWpGaD
Amphetamine—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.00174	0.0415	CbGpPWpGaD
Amphetamine—MAOB—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00142	0.034	CbGpPWpGaD
Amphetamine—CARTPT—Circadian rythm related genes—LEP—psoriasis	0.00119	0.0283	CbGpPWpGaD
Amphetamine—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.00115	0.0276	CbGpPWpGaD
Amphetamine—CARTPT—Circadian rythm related genes—NOS2—psoriasis	0.0011	0.0264	CbGpPWpGaD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.00104	0.0248	CbGpPWpGaD
Amphetamine—CARTPT—Circadian rythm related genes—PPARG—psoriasis	0.00103	0.0246	CbGpPWpGaD
Amphetamine—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000855	0.0204	CbGpPWpGaD
Amphetamine—CYP2A6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000844	0.0201	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—HCAR2—psoriasis	0.000792	0.0189	CbGpPWpGaD
Amphetamine—MAOB—Biological oxidations—CYP2S1—psoriasis	0.000756	0.018	CbGpPWpGaD
Amphetamine—CARTPT—Circadian rythm related genes—JUN—psoriasis	0.000733	0.0175	CbGpPWpGaD
Amphetamine—CYP2A6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000693	0.0165	CbGpPWpGaD
Amphetamine—MAOB—Tryptophan metabolism—CAT—psoriasis	0.000652	0.0156	CbGpPWpGaD
Amphetamine—SLC18A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.000599	0.0143	CbGpPWpGaD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.00054	0.0129	CbGpPWpGaD
Amphetamine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKBIA—psoriasis	0.000535	0.0128	CbGpPWpGaD
Amphetamine—Acute coronary syndrome—Prednisone—psoriasis	0.000522	0.00136	CcSEcCtD
Amphetamine—Dry mouth—Cyclosporine—psoriasis	0.000521	0.00136	CcSEcCtD
Amphetamine—Angioedema—Prednisolone—psoriasis	0.00052	0.00136	CcSEcCtD
Amphetamine—Chest pain—Mycophenolate mofetil—psoriasis	0.00052	0.00135	CcSEcCtD
Amphetamine—Myocardial infarction—Prednisone—psoriasis	0.000519	0.00135	CcSEcCtD
Amphetamine—Anxiety—Mycophenolate mofetil—psoriasis	0.000518	0.00135	CcSEcCtD
Amphetamine—SLC22A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.000518	0.0124	CbGpPWpGaD
Amphetamine—Toxic epidermal necrolysis—Methotrexate—psoriasis	0.000517	0.00135	CcSEcCtD
Amphetamine—Gastrointestinal pain—Mycophenolic acid—psoriasis	0.000516	0.00134	CcSEcCtD
Amphetamine—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.000516	0.0123	CbGpPWpGaD
Amphetamine—Diarrhoea—Hydroxyurea—psoriasis	0.000516	0.00134	CcSEcCtD
Amphetamine—Anaphylactic shock—Cyclosporine—psoriasis	0.000511	0.00133	CcSEcCtD
Amphetamine—Dry mouth—Mycophenolate mofetil—psoriasis	0.000508	0.00132	CcSEcCtD
Amphetamine—Angioedema—Hydrocortisone—psoriasis	0.000508	0.00132	CcSEcCtD
Amphetamine—Infection—Cyclosporine—psoriasis	0.000507	0.00132	CcSEcCtD
Amphetamine—Abdominal pain—Mycophenolic acid—psoriasis	0.000499	0.0013	CcSEcCtD
Amphetamine—Body temperature increased—Mycophenolic acid—psoriasis	0.000499	0.0013	CcSEcCtD
Amphetamine—Dizziness—Hydroxyurea—psoriasis	0.000498	0.0013	CcSEcCtD
Amphetamine—Anaphylactic shock—Mycophenolate mofetil—psoriasis	0.000498	0.0013	CcSEcCtD
Amphetamine—Infection—Mycophenolate mofetil—psoriasis	0.000495	0.00129	CcSEcCtD
Amphetamine—Hyperhidrosis—Cyclosporine—psoriasis	0.000494	0.00129	CcSEcCtD
Amphetamine—Convulsion—Prednisolone—psoriasis	0.000493	0.00129	CcSEcCtD
Amphetamine—Hypertension—Prednisolone—psoriasis	0.000492	0.00128	CcSEcCtD
Amphetamine—Anorexia—Cyclosporine—psoriasis	0.000487	0.00127	CcSEcCtD
Amphetamine—Tachycardia—Mycophenolate mofetil—psoriasis	0.000486	0.00127	CcSEcCtD
Amphetamine—CARTPT—Circadian rythm related genes—TP53—psoriasis	0.000484	0.0115	CbGpPWpGaD
Amphetamine—Convulsion—Hydrocortisone—psoriasis	0.000482	0.00126	CcSEcCtD
Amphetamine—Hyperhidrosis—Mycophenolate mofetil—psoriasis	0.000482	0.00125	CcSEcCtD
Amphetamine—Hypertension—Hydrocortisone—psoriasis	0.00048	0.00125	CcSEcCtD
Amphetamine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000479	0.0114	CbGpPWpGaD
Amphetamine—Vomiting—Hydroxyurea—psoriasis	0.000479	0.00125	CcSEcCtD
Amphetamine—Angioedema—Triamcinolone—psoriasis	0.000478	0.00125	CcSEcCtD
Amphetamine—Rash—Hydroxyurea—psoriasis	0.000475	0.00124	CcSEcCtD
Amphetamine—Anorexia—Mycophenolate mofetil—psoriasis	0.000475	0.00124	CcSEcCtD
Amphetamine—Dermatitis—Hydroxyurea—psoriasis	0.000475	0.00124	CcSEcCtD
Amphetamine—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000473	0.0113	CbGpPWpGaD
Amphetamine—Headache—Hydroxyurea—psoriasis	0.000472	0.00123	CcSEcCtD
Amphetamine—Anxiety—Hydrocortisone—psoriasis	0.000472	0.00123	CcSEcCtD
Amphetamine—Anaphylactic shock—Prednisolone—psoriasis	0.000465	0.00121	CcSEcCtD
Amphetamine—Insomnia—Cyclosporine—psoriasis	0.000462	0.0012	CcSEcCtD
Amphetamine—Erectile dysfunction—Methotrexate—psoriasis	0.000457	0.00119	CcSEcCtD
Amphetamine—Dyspnoea—Cyclosporine—psoriasis	0.000455	0.00119	CcSEcCtD
Amphetamine—Somnolence—Cyclosporine—psoriasis	0.000454	0.00118	CcSEcCtD
Amphetamine—Anaphylactic shock—Hydrocortisone—psoriasis	0.000454	0.00118	CcSEcCtD
Amphetamine—Convulsion—Triamcinolone—psoriasis	0.000454	0.00118	CcSEcCtD
Amphetamine—Tachycardia—Prednisolone—psoriasis	0.000454	0.00118	CcSEcCtD
Amphetamine—Photosensitivity reaction—Methotrexate—psoriasis	0.000453	0.00118	CcSEcCtD
Amphetamine—Asthenia—Mycophenolic acid—psoriasis	0.000453	0.00118	CcSEcCtD
Amphetamine—Hypertension—Triamcinolone—psoriasis	0.000452	0.00118	CcSEcCtD
Amphetamine—Infection—Hydrocortisone—psoriasis	0.000451	0.00117	CcSEcCtD
Amphetamine—Insomnia—Mycophenolate mofetil—psoriasis	0.000451	0.00117	CcSEcCtD
Amphetamine—Dyspepsia—Cyclosporine—psoriasis	0.00045	0.00117	CcSEcCtD
Amphetamine—Hyperhidrosis—Prednisolone—psoriasis	0.000449	0.00117	CcSEcCtD
Amphetamine—Nausea—Hydroxyurea—psoriasis	0.000448	0.00117	CcSEcCtD
Amphetamine—TAAR1—GPCR downstream signaling—HCAR2—psoriasis	0.000447	0.0107	CbGpPWpGaD
Amphetamine—Dyspnoea—Mycophenolate mofetil—psoriasis	0.000444	0.00116	CcSEcCtD
Amphetamine—Decreased appetite—Cyclosporine—psoriasis	0.000444	0.00116	CcSEcCtD
Amphetamine—Tachycardia—Hydrocortisone—psoriasis	0.000443	0.00115	CcSEcCtD
Amphetamine—Somnolence—Mycophenolate mofetil—psoriasis	0.000443	0.00115	CcSEcCtD
Amphetamine—CARTPT—Circadian rythm related genes—IL6—psoriasis	0.000443	0.0106	CbGpPWpGaD
Amphetamine—Depression—Methotrexate—psoriasis	0.000441	0.00115	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000441	0.00115	CcSEcCtD
Amphetamine—Fatigue—Cyclosporine—psoriasis	0.00044	0.00115	CcSEcCtD
Amphetamine—Hyperhidrosis—Hydrocortisone—psoriasis	0.000439	0.00114	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Methotrexate—psoriasis	0.000439	0.00114	CcSEcCtD
Amphetamine—Dyspepsia—Mycophenolate mofetil—psoriasis	0.000439	0.00114	CcSEcCtD
Amphetamine—Constipation—Cyclosporine—psoriasis	0.000437	0.00114	CcSEcCtD
Amphetamine—Dry mouth—Triamcinolone—psoriasis	0.000436	0.00114	CcSEcCtD
Amphetamine—Angioedema—Betamethasone—psoriasis	0.000434	0.00113	CcSEcCtD
Amphetamine—Angioedema—Dexamethasone—psoriasis	0.000434	0.00113	CcSEcCtD
Amphetamine—Decreased appetite—Mycophenolate mofetil—psoriasis	0.000433	0.00113	CcSEcCtD
Amphetamine—Anorexia—Hydrocortisone—psoriasis	0.000433	0.00113	CcSEcCtD
Amphetamine—Diarrhoea—Mycophenolic acid—psoriasis	0.000432	0.00113	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.00043	0.00112	CcSEcCtD
Amphetamine—Anaphylactic shock—Triamcinolone—psoriasis	0.000427	0.00111	CcSEcCtD
Amphetamine—Constipation—Mycophenolate mofetil—psoriasis	0.000426	0.00111	CcSEcCtD
Amphetamine—Infection—Triamcinolone—psoriasis	0.000425	0.00111	CcSEcCtD
Amphetamine—Sweating—Methotrexate—psoriasis	0.000424	0.00111	CcSEcCtD
Amphetamine—Insomnia—Prednisolone—psoriasis	0.00042	0.00109	CcSEcCtD
Amphetamine—Gastrointestinal pain—Cyclosporine—psoriasis	0.000418	0.00109	CcSEcCtD
Amphetamine—Dizziness—Mycophenolic acid—psoriasis	0.000417	0.00109	CcSEcCtD
Amphetamine—Tachycardia—Triamcinolone—psoriasis	0.000417	0.00109	CcSEcCtD
Amphetamine—Hyperhidrosis—Triamcinolone—psoriasis	0.000413	0.00108	CcSEcCtD
Amphetamine—Convulsion—Dexamethasone—psoriasis	0.000412	0.00107	CcSEcCtD
Amphetamine—Convulsion—Betamethasone—psoriasis	0.000412	0.00107	CcSEcCtD
Amphetamine—TAAR1—GPCR ligand binding—CCL20—psoriasis	0.000411	0.00981	CbGpPWpGaD
Amphetamine—Insomnia—Hydrocortisone—psoriasis	0.000411	0.00107	CcSEcCtD
Amphetamine—Hypertension—Dexamethasone—psoriasis	0.00041	0.00107	CcSEcCtD
Amphetamine—Hypertension—Betamethasone—psoriasis	0.00041	0.00107	CcSEcCtD
Amphetamine—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000407	0.00106	CcSEcCtD
Amphetamine—TAAR1—Signaling by GPCR—HCAR2—psoriasis	0.000406	0.00969	CbGpPWpGaD
Amphetamine—Urticaria—Cyclosporine—psoriasis	0.000406	0.00106	CcSEcCtD
Amphetamine—Abdominal pain—Cyclosporine—psoriasis	0.000404	0.00105	CcSEcCtD
Amphetamine—Body temperature increased—Cyclosporine—psoriasis	0.000404	0.00105	CcSEcCtD
Amphetamine—Anxiety—Betamethasone—psoriasis	0.000403	0.00105	CcSEcCtD
Amphetamine—Anxiety—Dexamethasone—psoriasis	0.000403	0.00105	CcSEcCtD
Amphetamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.000403	0.00961	CbGpPWpGaD
Amphetamine—Vomiting—Mycophenolic acid—psoriasis	0.000401	0.00105	CcSEcCtD
Amphetamine—Dyspepsia—Hydrocortisone—psoriasis	0.0004	0.00104	CcSEcCtD
Amphetamine—Rash—Mycophenolic acid—psoriasis	0.000398	0.00104	CcSEcCtD
Amphetamine—Dermatitis—Mycophenolic acid—psoriasis	0.000398	0.00104	CcSEcCtD
Amphetamine—Urticaria—Mycophenolate mofetil—psoriasis	0.000396	0.00103	CcSEcCtD
Amphetamine—Headache—Mycophenolic acid—psoriasis	0.000395	0.00103	CcSEcCtD
Amphetamine—Decreased appetite—Hydrocortisone—psoriasis	0.000395	0.00103	CcSEcCtD
Amphetamine—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000394	0.00103	CcSEcCtD
Amphetamine—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000394	0.00103	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000392	0.00102	CcSEcCtD
Amphetamine—Fatigue—Hydrocortisone—psoriasis	0.000391	0.00102	CcSEcCtD
Amphetamine—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000389	0.00927	CbGpPWpGaD
Amphetamine—Anaphylactic shock—Dexamethasone—psoriasis	0.000388	0.00101	CcSEcCtD
Amphetamine—Anaphylactic shock—Betamethasone—psoriasis	0.000388	0.00101	CcSEcCtD
Amphetamine—Insomnia—Triamcinolone—psoriasis	0.000387	0.00101	CcSEcCtD
Amphetamine—Infection—Betamethasone—psoriasis	0.000385	0.001	CcSEcCtD
Amphetamine—Infection—Dexamethasone—psoriasis	0.000385	0.001	CcSEcCtD
Amphetamine—Dyspnoea—Triamcinolone—psoriasis	0.000381	0.000992	CcSEcCtD
Amphetamine—Agitation—Prednisone—psoriasis	0.00038	0.000991	CcSEcCtD
Amphetamine—Tachycardia—Betamethasone—psoriasis	0.000378	0.000986	CcSEcCtD
Amphetamine—Tachycardia—Dexamethasone—psoriasis	0.000378	0.000986	CcSEcCtD
Amphetamine—Angioedema—Prednisone—psoriasis	0.000378	0.000985	CcSEcCtD
Amphetamine—Hypersensitivity—Cyclosporine—psoriasis	0.000376	0.00098	CcSEcCtD
Amphetamine—Dyspepsia—Triamcinolone—psoriasis	0.000376	0.00098	CcSEcCtD
Amphetamine—Erythema multiforme—Methotrexate—psoriasis	0.000376	0.000978	CcSEcCtD
Amphetamine—Nausea—Mycophenolic acid—psoriasis	0.000375	0.000977	CcSEcCtD
Amphetamine—Hyperhidrosis—Betamethasone—psoriasis	0.000375	0.000976	CcSEcCtD
Amphetamine—Hyperhidrosis—Dexamethasone—psoriasis	0.000375	0.000976	CcSEcCtD
Amphetamine—SLC18A2—Dopaminergic Neurogenesis—STAT3—psoriasis	0.000373	0.0089	CbGpPWpGaD
Amphetamine—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000371	0.000967	CcSEcCtD
Amphetamine—Anorexia—Dexamethasone—psoriasis	0.00037	0.000963	CcSEcCtD
Amphetamine—Anorexia—Betamethasone—psoriasis	0.00037	0.000963	CcSEcCtD
Amphetamine—Urticaria—Prednisolone—psoriasis	0.000369	0.000962	CcSEcCtD
Amphetamine—Fatigue—Triamcinolone—psoriasis	0.000368	0.00096	CcSEcCtD
Amphetamine—CYP2A6—Biological oxidations—CYP2S1—psoriasis	0.000368	0.00879	CbGpPWpGaD
Amphetamine—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000367	0.000956	CcSEcCtD
Amphetamine—Asthenia—Cyclosporine—psoriasis	0.000366	0.000954	CcSEcCtD
Amphetamine—Urticaria—Hydrocortisone—psoriasis	0.000361	0.000939	CcSEcCtD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.000359	0.00857	CbGpPWpGaD
Amphetamine—Abdominal pain—Hydrocortisone—psoriasis	0.000359	0.000935	CcSEcCtD
Amphetamine—Body temperature increased—Hydrocortisone—psoriasis	0.000359	0.000935	CcSEcCtD
Amphetamine—Convulsion—Prednisone—psoriasis	0.000359	0.000934	CcSEcCtD
Amphetamine—Asthenia—Mycophenolate mofetil—psoriasis	0.000357	0.000931	CcSEcCtD
Amphetamine—Hypertension—Prednisone—psoriasis	0.000357	0.000931	CcSEcCtD
Amphetamine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.000357	0.00851	CbGpPWpGaD
Amphetamine—Pseudoephedrine—TNF—psoriasis	0.000355	0.505	CrCbGaD
Amphetamine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—psoriasis	0.000355	0.00847	CbGpPWpGaD
Amphetamine—Anxiety—Prednisone—psoriasis	0.000351	0.000914	CcSEcCtD
Amphetamine—Insomnia—Dexamethasone—psoriasis	0.000351	0.000914	CcSEcCtD
Amphetamine—Insomnia—Betamethasone—psoriasis	0.000351	0.000914	CcSEcCtD
Amphetamine—Diarrhoea—Cyclosporine—psoriasis	0.000349	0.00091	CcSEcCtD
Amphetamine—Nateglinide—PPARG—psoriasis	0.000349	0.495	CrCbGaD
Amphetamine—Hypersensitivity—Prednisolone—psoriasis	0.000342	0.000892	CcSEcCtD
Amphetamine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKB1—psoriasis	0.000342	0.00815	CbGpPWpGaD
Amphetamine—Dyspepsia—Dexamethasone—psoriasis	0.000341	0.000889	CcSEcCtD
Amphetamine—Dyspepsia—Betamethasone—psoriasis	0.000341	0.000889	CcSEcCtD
Amphetamine—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000341	0.000888	CcSEcCtD
Amphetamine—Urticaria—Triamcinolone—psoriasis	0.00034	0.000884	CcSEcCtD
Amphetamine—Body temperature increased—Triamcinolone—psoriasis	0.000338	0.00088	CcSEcCtD
Amphetamine—Dizziness—Cyclosporine—psoriasis	0.000338	0.00088	CcSEcCtD
Amphetamine—Anaphylactic shock—Prednisone—psoriasis	0.000338	0.00088	CcSEcCtD
Amphetamine—Decreased appetite—Dexamethasone—psoriasis	0.000337	0.000878	CcSEcCtD
Amphetamine—Decreased appetite—Betamethasone—psoriasis	0.000337	0.000878	CcSEcCtD
Amphetamine—Infection—Prednisone—psoriasis	0.000335	0.000874	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000335	0.000872	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Betamethasone—psoriasis	0.000335	0.000872	CcSEcCtD
Amphetamine—Hypersensitivity—Hydrocortisone—psoriasis	0.000334	0.000871	CcSEcCtD
Amphetamine—Fatigue—Dexamethasone—psoriasis	0.000334	0.000871	CcSEcCtD
Amphetamine—Fatigue—Betamethasone—psoriasis	0.000334	0.000871	CcSEcCtD
Amphetamine—Tachycardia—Prednisone—psoriasis	0.00033	0.000859	CcSEcCtD
Amphetamine—Dizziness—Mycophenolate mofetil—psoriasis	0.000329	0.000858	CcSEcCtD
Amphetamine—Hyperhidrosis—Prednisone—psoriasis	0.000326	0.00085	CcSEcCtD
Amphetamine—Asthenia—Hydrocortisone—psoriasis	0.000326	0.000848	CcSEcCtD
Amphetamine—Vomiting—Cyclosporine—psoriasis	0.000325	0.000846	CcSEcCtD
Amphetamine—SLC6A4—NRF2 pathway—TGFA—psoriasis	0.000322	0.00769	CbGpPWpGaD
Amphetamine—Rash—Cyclosporine—psoriasis	0.000322	0.000839	CcSEcCtD
Amphetamine—Anorexia—Prednisone—psoriasis	0.000322	0.000839	CcSEcCtD
Amphetamine—Dermatitis—Cyclosporine—psoriasis	0.000322	0.000838	CcSEcCtD
Amphetamine—Headache—Cyclosporine—psoriasis	0.00032	0.000833	CcSEcCtD
Amphetamine—Gastrointestinal pain—Dexamethasone—psoriasis	0.000317	0.000826	CcSEcCtD
Amphetamine—Gastrointestinal pain—Betamethasone—psoriasis	0.000317	0.000826	CcSEcCtD
Amphetamine—Vomiting—Mycophenolate mofetil—psoriasis	0.000317	0.000825	CcSEcCtD
Amphetamine—Hypersensitivity—Triamcinolone—psoriasis	0.000315	0.00082	CcSEcCtD
Amphetamine—Rash—Mycophenolate mofetil—psoriasis	0.000314	0.000818	CcSEcCtD
Amphetamine—Dermatitis—Mycophenolate mofetil—psoriasis	0.000314	0.000817	CcSEcCtD
Amphetamine—Headache—Mycophenolate mofetil—psoriasis	0.000312	0.000813	CcSEcCtD
Amphetamine—Diarrhoea—Hydrocortisone—psoriasis	0.000311	0.000809	CcSEcCtD
Amphetamine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—psoriasis	0.00031	0.0074	CbGpPWpGaD
Amphetamine—Urticaria—Dexamethasone—psoriasis	0.000308	0.000802	CcSEcCtD
Amphetamine—Urticaria—Betamethasone—psoriasis	0.000308	0.000802	CcSEcCtD
Amphetamine—Dizziness—Prednisolone—psoriasis	0.000307	0.000801	CcSEcCtD
Amphetamine—Asthenia—Triamcinolone—psoriasis	0.000307	0.000799	CcSEcCtD
Amphetamine—Body temperature increased—Betamethasone—psoriasis	0.000307	0.000799	CcSEcCtD
Amphetamine—Abdominal pain—Betamethasone—psoriasis	0.000307	0.000799	CcSEcCtD
Amphetamine—Body temperature increased—Dexamethasone—psoriasis	0.000307	0.000799	CcSEcCtD
Amphetamine—Abdominal pain—Dexamethasone—psoriasis	0.000307	0.000799	CcSEcCtD
Amphetamine—Insomnia—Prednisone—psoriasis	0.000305	0.000796	CcSEcCtD
Amphetamine—DRD2—G alpha (i) signalling events—HCAR2—psoriasis	0.000305	0.00728	CbGpPWpGaD
Amphetamine—Nausea—Cyclosporine—psoriasis	0.000303	0.00079	CcSEcCtD
Amphetamine—Dizziness—Hydrocortisone—psoriasis	0.0003	0.000782	CcSEcCtD
Amphetamine—Convulsion—Methotrexate—psoriasis	0.0003	0.00078	CcSEcCtD
Amphetamine—Dyspepsia—Prednisone—psoriasis	0.000297	0.000774	CcSEcCtD
Amphetamine—Nausea—Mycophenolate mofetil—psoriasis	0.000296	0.000771	CcSEcCtD
Amphetamine—Chest pain—Methotrexate—psoriasis	0.000294	0.000767	CcSEcCtD
Amphetamine—Decreased appetite—Prednisone—psoriasis	0.000294	0.000765	CcSEcCtD
Amphetamine—Rash—Prednisolone—psoriasis	0.000293	0.000763	CcSEcCtD
Amphetamine—Dermatitis—Prednisolone—psoriasis	0.000293	0.000763	CcSEcCtD
Amphetamine—Fatigue—Prednisone—psoriasis	0.000291	0.000758	CcSEcCtD
Amphetamine—Headache—Prednisolone—psoriasis	0.000291	0.000758	CcSEcCtD
Amphetamine—Constipation—Prednisone—psoriasis	0.000289	0.000752	CcSEcCtD
Amphetamine—Vomiting—Hydrocortisone—psoriasis	0.000289	0.000752	CcSEcCtD
Amphetamine—Rash—Hydrocortisone—psoriasis	0.000286	0.000745	CcSEcCtD
Amphetamine—Dermatitis—Hydrocortisone—psoriasis	0.000286	0.000745	CcSEcCtD
Amphetamine—Headache—Hydrocortisone—psoriasis	0.000284	0.000741	CcSEcCtD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—IL13—psoriasis	0.000284	0.00677	CbGpPWpGaD
Amphetamine—Dizziness—Triamcinolone—psoriasis	0.000283	0.000736	CcSEcCtD
Amphetamine—Anaphylactic shock—Methotrexate—psoriasis	0.000282	0.000735	CcSEcCtD
Amphetamine—Infection—Methotrexate—psoriasis	0.00028	0.00073	CcSEcCtD
Amphetamine—Asthenia—Dexamethasone—psoriasis	0.000278	0.000725	CcSEcCtD
Amphetamine—Asthenia—Betamethasone—psoriasis	0.000278	0.000725	CcSEcCtD
Amphetamine—SLC6A2—NRF2 pathway—TGFA—psoriasis	0.000277	0.00661	CbGpPWpGaD
Amphetamine—Gastrointestinal pain—Prednisone—psoriasis	0.000276	0.000719	CcSEcCtD
Amphetamine—Nausea—Prednisolone—psoriasis	0.000276	0.000719	CcSEcCtD
Amphetamine—Hyperhidrosis—Methotrexate—psoriasis	0.000273	0.000711	CcSEcCtD
Amphetamine—SLC18A2—SLC-mediated transmembrane transport—CP—psoriasis	0.000272	0.00649	CbGpPWpGaD
Amphetamine—Vomiting—Triamcinolone—psoriasis	0.000272	0.000708	CcSEcCtD
Amphetamine—Nausea—Hydrocortisone—psoriasis	0.00027	0.000702	CcSEcCtD
Amphetamine—Rash—Triamcinolone—psoriasis	0.000269	0.000702	CcSEcCtD
Amphetamine—Dermatitis—Triamcinolone—psoriasis	0.000269	0.000701	CcSEcCtD
Amphetamine—Anorexia—Methotrexate—psoriasis	0.000269	0.000701	CcSEcCtD
Amphetamine—Urticaria—Prednisone—psoriasis	0.000268	0.000699	CcSEcCtD
Amphetamine—Headache—Triamcinolone—psoriasis	0.000268	0.000697	CcSEcCtD
Amphetamine—Abdominal pain—Prednisone—psoriasis	0.000267	0.000695	CcSEcCtD
Amphetamine—Body temperature increased—Prednisone—psoriasis	0.000267	0.000695	CcSEcCtD
Amphetamine—Diarrhoea—Dexamethasone—psoriasis	0.000265	0.000691	CcSEcCtD
Amphetamine—Diarrhoea—Betamethasone—psoriasis	0.000265	0.000691	CcSEcCtD
Amphetamine—Dizziness—Betamethasone—psoriasis	0.000256	0.000668	CcSEcCtD
Amphetamine—Dizziness—Dexamethasone—psoriasis	0.000256	0.000668	CcSEcCtD
Amphetamine—Insomnia—Methotrexate—psoriasis	0.000255	0.000665	CcSEcCtD
Amphetamine—Nausea—Triamcinolone—psoriasis	0.000254	0.000661	CcSEcCtD
Amphetamine—Dyspnoea—Methotrexate—psoriasis	0.000252	0.000655	CcSEcCtD
Amphetamine—Somnolence—Methotrexate—psoriasis	0.000251	0.000654	CcSEcCtD
Amphetamine—Hypersensitivity—Prednisone—psoriasis	0.000249	0.000648	CcSEcCtD
Amphetamine—Dyspepsia—Methotrexate—psoriasis	0.000248	0.000647	CcSEcCtD
Amphetamine—Vomiting—Dexamethasone—psoriasis	0.000247	0.000642	CcSEcCtD
Amphetamine—Vomiting—Betamethasone—psoriasis	0.000247	0.000642	CcSEcCtD
Amphetamine—SLC6A3—NRF2 pathway—TGFA—psoriasis	0.000245	0.00586	CbGpPWpGaD
Amphetamine—Decreased appetite—Methotrexate—psoriasis	0.000245	0.000639	CcSEcCtD
Amphetamine—Rash—Betamethasone—psoriasis	0.000245	0.000637	CcSEcCtD
Amphetamine—Rash—Dexamethasone—psoriasis	0.000245	0.000637	CcSEcCtD
Amphetamine—Dermatitis—Dexamethasone—psoriasis	0.000244	0.000636	CcSEcCtD
Amphetamine—Dermatitis—Betamethasone—psoriasis	0.000244	0.000636	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Methotrexate—psoriasis	0.000244	0.000635	CcSEcCtD
Amphetamine—Fatigue—Methotrexate—psoriasis	0.000243	0.000634	CcSEcCtD
Amphetamine—Headache—Dexamethasone—psoriasis	0.000243	0.000633	CcSEcCtD
Amphetamine—Headache—Betamethasone—psoriasis	0.000243	0.000633	CcSEcCtD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000242	0.00578	CbGpPWpGaD
Amphetamine—Asthenia—Prednisone—psoriasis	0.000242	0.000631	CcSEcCtD
Amphetamine—TAAR1—Signaling Pathways—HCAR2—psoriasis	0.00024	0.00573	CbGpPWpGaD
Amphetamine—SLC6A4—Monoamine Transport—TNF—psoriasis	0.00024	0.00572	CbGpPWpGaD
Amphetamine—SLC22A3—SLC-mediated transmembrane transport—CP—psoriasis	0.000235	0.00561	CbGpPWpGaD
Amphetamine—SLC22A5—SLC-mediated transmembrane transport—CP—psoriasis	0.000234	0.00559	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—CCL20—psoriasis	0.000232	0.00554	CbGpPWpGaD
Amphetamine—Diarrhoea—Prednisone—psoriasis	0.000231	0.000602	CcSEcCtD
Amphetamine—Gastrointestinal pain—Methotrexate—psoriasis	0.000231	0.000601	CcSEcCtD
Amphetamine—Nausea—Dexamethasone—psoriasis	0.00023	0.0006	CcSEcCtD
Amphetamine—Nausea—Betamethasone—psoriasis	0.00023	0.0006	CcSEcCtD
Amphetamine—Urticaria—Methotrexate—psoriasis	0.000224	0.000584	CcSEcCtD
Amphetamine—Dizziness—Prednisone—psoriasis	0.000223	0.000582	CcSEcCtD
Amphetamine—Abdominal pain—Methotrexate—psoriasis	0.000223	0.000581	CcSEcCtD
Amphetamine—Body temperature increased—Methotrexate—psoriasis	0.000223	0.000581	CcSEcCtD
Amphetamine—SLC6A3—Dopaminergic Neurogenesis—STAT3—psoriasis	0.000222	0.0053	CbGpPWpGaD
Amphetamine—Vomiting—Prednisone—psoriasis	0.000215	0.000559	CcSEcCtD
Amphetamine—Rash—Prednisone—psoriasis	0.000213	0.000555	CcSEcCtD
Amphetamine—Dermatitis—Prednisone—psoriasis	0.000213	0.000554	CcSEcCtD
Amphetamine—Headache—Prednisone—psoriasis	0.000212	0.000551	CcSEcCtD
Amphetamine—TAAR1—Signaling by GPCR—CCL20—psoriasis	0.000211	0.00503	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—TAGAP—psoriasis	0.000208	0.00496	CbGpPWpGaD
Amphetamine—Hypersensitivity—Methotrexate—psoriasis	0.000208	0.000542	CcSEcCtD
Amphetamine—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.000206	0.00493	CbGpPWpGaD
Amphetamine—SLC6A2—Monoamine Transport—TNF—psoriasis	0.000206	0.00492	CbGpPWpGaD
Amphetamine—CYP2A6—NRF2 pathway—TGFA—psoriasis	0.000205	0.00489	CbGpPWpGaD
Amphetamine—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.000204	0.00486	CbGpPWpGaD
Amphetamine—Asthenia—Methotrexate—psoriasis	0.000202	0.000527	CcSEcCtD
Amphetamine—Nausea—Prednisone—psoriasis	0.000201	0.000523	CcSEcCtD
Amphetamine—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.0002	0.00478	CbGpPWpGaD
Amphetamine—Diarrhoea—Methotrexate—psoriasis	0.000193	0.000503	CcSEcCtD
Amphetamine—Dizziness—Methotrexate—psoriasis	0.000187	0.000486	CcSEcCtD
Amphetamine—DRD2—GPCR ligand binding—HCAR2—psoriasis	0.000185	0.00441	CbGpPWpGaD
Amphetamine—SLC6A2—SLC-mediated transmembrane transport—CP—psoriasis	0.000183	0.00437	CbGpPWpGaD
Amphetamine—SLC6A3—Monoamine Transport—TNF—psoriasis	0.000183	0.00436	CbGpPWpGaD
Amphetamine—Vomiting—Methotrexate—psoriasis	0.000179	0.000467	CcSEcCtD
Amphetamine—Rash—Methotrexate—psoriasis	0.000178	0.000464	CcSEcCtD
Amphetamine—Dermatitis—Methotrexate—psoriasis	0.000178	0.000463	CcSEcCtD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—IL10—psoriasis	0.000177	0.00423	CbGpPWpGaD
Amphetamine—Headache—Methotrexate—psoriasis	0.000177	0.000461	CcSEcCtD
Amphetamine—Nausea—Methotrexate—psoriasis	0.000168	0.000437	CcSEcCtD
Amphetamine—SLC6A3—SLC-mediated transmembrane transport—CP—psoriasis	0.000162	0.00387	CbGpPWpGaD
Amphetamine—DRD2—G alpha (i) signalling events—CCL20—psoriasis	0.000158	0.00378	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—NDUFA5—psoriasis	0.000152	0.00363	CbGpPWpGaD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.000146	0.00348	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—CP—psoriasis	0.000138	0.0033	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—CARM1—psoriasis	0.000132	0.00315	CbGpPWpGaD
Amphetamine—CYP2A6—Fluoropyrimidine Activity—TP53—psoriasis	0.000131	0.00313	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—CYP2S1—psoriasis	0.000129	0.00308	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—NDUFA5—psoriasis	0.000129	0.00307	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000126	0.003	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CCL20—psoriasis	0.000125	0.00297	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—CP—psoriasis	0.00012	0.00285	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—LEP—psoriasis	0.000119	0.00284	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—CP—psoriasis	0.000119	0.00284	CbGpPWpGaD
Amphetamine—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	0.000119	0.00284	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—CARM1—psoriasis	0.000114	0.00272	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—CARM1—psoriasis	0.000114	0.00271	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—NOS2—psoriasis	0.000111	0.00265	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—CXCL8—psoriasis	0.000111	0.00265	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CYP2S1—psoriasis	0.000109	0.00261	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—HCAR2—psoriasis	0.000104	0.00249	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—PPARG—psoriasis	0.000104	0.00248	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—CXCL8—psoriasis	9.7e-05	0.00232	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—CCL20—psoriasis	9.59e-05	0.00229	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—HCAR2—psoriasis	9.47e-05	0.00226	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—CP—psoriasis	9.3e-05	0.00222	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—JUN—psoriasis	9.02e-05	0.00215	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—CARM1—psoriasis	8.87e-05	0.00212	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—NFKB1—psoriasis	8.68e-05	0.00207	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—CP—psoriasis	8.24e-05	0.00197	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—VEGFA—psoriasis	7.88e-05	0.00188	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—CARM1—psoriasis	7.86e-05	0.00188	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—NDUFA5—psoriasis	7.4e-05	0.00177	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—JUN—psoriasis	7.36e-05	0.00176	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—LEP—psoriasis	7.29e-05	0.00174	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—SOCS1—psoriasis	6.86e-05	0.00164	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—NOS2—psoriasis	6.8e-05	0.00162	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—TNF—psoriasis	6.75e-05	0.00161	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—TYK2—psoriasis	6.54e-05	0.00156	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—PPARG—psoriasis	6.35e-05	0.00152	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—CARM1—psoriasis	6.31e-05	0.00151	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CYP2S1—psoriasis	6.3e-05	0.0015	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—CXCL8—psoriasis	6.27e-05	0.0015	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—CXCL8—psoriasis	5.7e-05	0.00136	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HCAR2—psoriasis	5.6e-05	0.00134	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—IL6—psoriasis	5.45e-05	0.0013	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—CCL20—psoriasis	5.42e-05	0.00129	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CARM1—psoriasis	5.34e-05	0.00127	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—LEP—psoriasis	5.06e-05	0.00121	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—APOE—psoriasis	5.06e-05	0.00121	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CCL20—psoriasis	4.92e-05	0.00117	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—TP53—psoriasis	4.86e-05	0.00116	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TAGAP—psoriasis	4.85e-05	0.00116	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—NFKBIA—psoriasis	4.72e-05	0.00113	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—JUN—psoriasis	4.51e-05	0.00108	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—IL6—psoriasis	4.45e-05	0.00106	CbGpPWpGaD
Amphetamine—DRD2—G alpha (i) signalling events—CXCL8—psoriasis	4.28e-05	0.00102	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—NDUFA5—psoriasis	4.15e-05	0.000991	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—CAT—psoriasis	3.88e-05	0.000926	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—TYK2—psoriasis	3.87e-05	0.000922	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CYP2S1—psoriasis	3.53e-05	0.000843	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	3.4e-05	0.000811	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CXCL8—psoriasis	3.37e-05	0.000803	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CAT—psoriasis	3.28e-05	0.000784	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—IL6—psoriasis	3.2e-05	0.000764	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—JUN—psoriasis	3.13e-05	0.000747	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CARM1—psoriasis	3.07e-05	0.000734	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—APOE—psoriasis	3.02e-05	0.00072	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—NFKB1—psoriasis	3.01e-05	0.000719	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—TP53—psoriasis	2.97e-05	0.00071	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CCL20—psoriasis	2.91e-05	0.000694	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—VEGFA—psoriasis	2.73e-05	0.000652	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—IL6—psoriasis	2.72e-05	0.00065	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—STAT3—psoriasis	2.71e-05	0.000646	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PPARG—psoriasis	2.63e-05	0.000627	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—CXCL8—psoriasis	2.59e-05	0.000618	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—APOE—psoriasis	2.55e-05	0.000609	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PPARG—psoriasis	2.22e-05	0.00053	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—TP53—psoriasis	2.07e-05	0.000493	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CAT—psoriasis	1.89e-05	0.000451	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—IL6—psoriasis	1.89e-05	0.000451	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CARM1—psoriasis	1.72e-05	0.000411	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—SOCS1—psoriasis	1.6e-05	0.000382	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—TYK2—psoriasis	1.53e-05	0.000364	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—APOE—psoriasis	1.47e-05	0.000351	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—CXCL8—psoriasis	1.46e-05	0.000349	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CXCL8—psoriasis	1.33e-05	0.000317	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PPARG—psoriasis	1.28e-05	0.000305	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—APOE—psoriasis	1.18e-05	0.000282	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—LEP—psoriasis	1.18e-05	0.000282	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NFKBIA—psoriasis	1.1e-05	0.000263	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CAT—psoriasis	1.06e-05	0.000253	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TYK2—psoriasis	9.02e-06	0.000215	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—APOE—psoriasis	8.24e-06	0.000197	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CXCL8—psoriasis	7.85e-06	0.000187	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—IL6—psoriasis	7.46e-06	0.000178	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—JUN—psoriasis	7.3e-06	0.000174	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PPARG—psoriasis	7.18e-06	0.000171	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NFKB1—psoriasis	7.02e-06	0.000168	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—VEGFA—psoriasis	6.38e-06	0.000152	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—STAT3—psoriasis	6.31e-06	0.000151	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TP53—psoriasis	4.82e-06	0.000115	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IL6—psoriasis	4.41e-06	0.000105	CbGpPWpGaD
